Trevi Therapeutics (NASDAQ:TRVI), a clinical-stage biopharma focused on treatments for cough conditions, traded higher on Wednesday after B. Riley, with a Buy rating, reportedly highlighted the company’s deal prospects following the recent departure of its CFO.
“We are going to